Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label, phase 2, multicenter, randomized trial of LVGN7409 plus docetaxel or, in combination with nivolumab in patients with advanced/metastatic Non-Small Cell Lung Cancer (NSCLC)

Next Previous
Trial Profile

An open label, phase 2, multicenter, randomized trial of LVGN7409 plus docetaxel or, in combination with nivolumab in patients with advanced/metastatic Non-Small Cell Lung Cancer (NSCLC)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dalnicastobart (Primary) ; Docetaxel (Primary) ; Nivolumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Lyvgen Biopharma

Most Recent Events

  • 29 Nov 2022 New trial record
  • 27 Nov 2022 According to a Lyvgen Biopharma media release, Under the terms of the Agreement, Lyvgen will sponsor the study and Bristol Myers Squibb will provide nivolumab for the combination trial.
  • 27 Nov 2022 According to a Lyvgen Biopharma media release, the company announced a Phase 2 clinical collaboration with Bristol Myers Squibb to evaluate LVGN7409 in combination with nivolumab in Non-Small Cell Lung Cancer patients. The study is expected to begin in 1st half 2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top